These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1799917)

  • 1. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
    Kays MB; White RL; Friedrich LV; Del Bene VE
    Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different statistical methodologies on the evaluation of the in-vitro MICs for Bacteroides fragilis of selected cephalosporins and cephamycins.
    White RL; Kays MB; Friedrich LV; Del Bene VE
    J Antimicrob Chemother; 1993 Jan; 31(1):57-64. PubMed ID: 8444675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.
    Jones RN; Barry AL; Aldridge KE; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Nov; 8(3):157-63. PubMed ID: 3501976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
    Edmiston CE; Krepel CJ; Clausz JC; Condon RE
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of susceptibility results of the Bacteroides fragilis group and other anaerobes by traditional MIC results and statistical methods.
    Aldridge KE; Johnson WD
    J Antimicrob Chemother; 1997 Mar; 39(3):319-24. PubMed ID: 9096180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
    Aldridge KE; Stratton CW
    J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis.
    Kesado T; Watanabe K; Asahi Y; Isono M; Ueno K
    Antimicrob Agents Chemother; 1984 Jan; 25(1):131-3. PubMed ID: 6322676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
    Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotetan: a review of the microbiologic properties and antimicrobial spectrum.
    Jones RN
    Am J Surg; 1988 May; 155(5A):16-23. PubMed ID: 3287964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacteroides and beta-lactamase inhibitory activities of moxalactam.
    Fu KP; Neu HC
    J Antimicrob Chemother; 1981 Oct; 8(4):337-41. PubMed ID: 6271727
    [No Abstract]   [Full Text] [Related]  

  • 17. A multicenter study of the in vitro antianaerobic activity of cefotetan compared with other antimicrobial agents.
    Zabransky RJ; Bobey DG; Sheikh W
    Am J Surg; 1988 May; 155(5A):47-51. PubMed ID: 3163901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-antibiotic effect in Bacteroides fragilis group.
    Siverhus DJ; Edmiston CE; Clausz JC; Goheen MP
    Ann Clin Lab Sci; 1988; 18(4):326-36. PubMed ID: 3165611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of intestinal anaerobes to new beta-lactam antibiotics.
    Bansal MB; Chuah SK; Thadepalli H
    Chemotherapy; 1984; 30(4):237-43. PubMed ID: 6744975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.